Esquirol Hsopital Center
Limoges, New Aquitaine, 87025, France
Location status: Recruiting
Location contact
Aude Paquet, PhD in Psychology
CONTACT
Théodore Vinais, Master degree
CONTACT
+33 + 5-87-50-91-29
NCT Number: NCT06839950
This descriptive study aims primarily to characterize the sensory profile of patients in a closed psychiatric hospital unit who use a calming room.
The main questions it aims to answer are :
* Could sensory information processing disorders be the cause of distress and tension in these patients? * Could users of the calming room present extreme sensory processing profiles, characterized by either hypersensitivity or hyposensitivity ?
Participants will answer a survey to determine their the sensory profile. Participants can already use the calming room as part of their regular medical care and they will answer surveys before and after each use.
Interested in participating?
Request Info18 year–65 year
All sexes
Observational
Limoges, New Aquitaine, 87025, France
Location status: Recruiting
Aude Paquet, PhD in Psychology
CONTACT
Théodore Vinais, Master degree
CONTACT
+33 + 5-87-50-91-29
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The calm room combines the effects of music, light, and videos designed with natural atmospheres. Four themes are offered in the calm room: Comfort, Optimism, Freshness, and Lullaby. These themes feature nature videos, combining relaxing images with calm musical ambiance. The lighting can be adjusted by the user, who can choose from a varied color palette. The available lights have a low glare level, and the light intensity can also be adjusted by the user.
They can be used by patients any time they want and for as long as they want.
Other names: Sensory room, Comfort room
Time frame: At enrollment
The sensory profile scores will be obtained through the Adolescent/Adult Sensory Profile (AASP) scale during an individual interview following the participant inclusion. The following Sensory Sensitivity sub-score will be collected. The minimum and maximum values are from 15 to 75. A high score indicate a high sensory sensitivity.
Time frame: At enrollment
The sensory profile scores will be obtained through the Adolescent/Adult Sensory Profile (AASP) scale during an individual interview following the participant inclusion. The following Low Registration sub-score will be collected. The minimum and maximum values are from 15 to 75. A high score indicate a high Low Registration.
Time frame: At enrollment
The sensory profile scores will be obtained through the Adolescent/Adult Sensory Profile (AASP) scale during an individual interview following the participant inclusion. The following Sensation Seeking sub-score will be collected. The minimum and maximum values are from 15 to 75. A high score indicate a high Sensation Seeking.
Time frame: At enrollment
The sensory profile scores will be obtained through the Adolescent/Adult Sensory Profile (AASP) scale during an individual interview following the participant inclusion. The following Sensation Avoiding sub-score will be collected. The minimum and maximum values are from 15 to 75. A high score indicate a high Sensation Avoiding.
Time frame: From enrollment to the end of observation at 2 weeks
Time frame: From enrollment to the end of observation at 2 weeks
Anxiety is assessed from the Hamilton Anxiety Rating Scale for users and non-users of the calming room.
The overall score ranges from 0 to 60. The generally accepted threshold for significant anxiety is 20.
Time frame: From enrollment to the end of observation at 2 weeks
Time frame: From enrollment to the end of observation at 2 weeks
Modes of use of the calming room among patients who use this room.
Qualitative measure is used for initiative :
Patient initiative or team initiative
Time frame: From enrollment to the end of observation at 2 weeks
Modes of use of the calming room among patients who use this room.
Qualitative measure is used for reason for resquesting use of the calming room :
Anxiety / Sadness / Fatigue / Physical Tension / Seeking Well-being
Time frame: From enrollment to the end of observation at 2 weeks
Modes of use of the calming room among patients who use this room.
Qualitative measure is used for autonomy for the use of the calming room :
Presence of caregiver / Partial autonomy (one-off intervention by a caregiver) / Total autonomy (nocaregiver intervention during the use)
Time frame: From enrollment to the end of observation at 2 weeks
Number of uses of the calming room during the hospitalization
Time frame: From enrollment to the the end of observation at 2 weeks
Description of early clinical signs leading to the use of the calming room among patients who use this room.
Visual Analog Score for anxiety
Time frame: From enrollment to the the end of observation at 2 weeks
Description of early clinical signs leading to the use of the calming room among patients who use this room.
Time frame: From enrollment to the the end of observation at 2 weeks
Description of early clinical signs leading to the use of the calming room among patients who use this room.
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Esquirol
Other
Acronym: EVAL-APAISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05656469
Anxiety Disorders, Mental Disorders
Syracuse, New York, United States
View Trial DetailsNCT06929442
Anxiety Disorders, Mental Disorders
Charlestown, Massachusetts, United States
View Trial DetailsNCT06360562
Anxiety Disorders, Mental Disorders
Charlestown, Massachusetts, United States
View Trial DetailsNCT02751632
Clinical High Risk, Mental Disorders
Craigieburn, Victoria, Australia
View Trial Details